PAVmed Inc. [NASDAQ: PAVM] closed the trading session at $2.47 on 02/09/21. The day’s price range saw the stock hit a low of $2.30, while the highest price level was $2.57. The company report on February 9, 2021 that PAVmed to Hold Business Update Conference Call on February 22, 2021.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, announced that the Company will host a business update conference call on Monday, February 22, 2021 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s President and Chief Financial Officer, will discuss fourth quarter 2020 financial results.
To access the conference call, U.S.-based listeners should dial (877) 407-3982 and international listeners should dial (201) 493-6780. All listeners should provide the operator with the conference call name “PAVmed, Inc. Business Update Conference Call” to join. Individuals interested in listening to the live conference call via webcast may do so by visiting the investor relations section of the Company’s website at www.pavmed.com.
The stocks have a year to date performance of 16.51 percent and weekly performance of 16.51 percent. The stock has been moved at 18.18 percent over the last six months. The stock has performed 15.96 percent around the most recent 30 days and changed 41.55 percent over the most recent 3-months.
If compared to the average trading volume of 1.81M shares, PAVM reached to a volume of 11732236 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about PAVmed Inc. [PAVM]:
Ascendiant Capital Markets have made an estimate for PAVmed Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 05, 2020. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on June 28, 2018, representing the official price target for PAVmed Inc. stock.
The Average True Range (ATR) for PAVmed Inc. is set at 0.17
PAVM stock trade performance evaluation
PAVmed Inc. [PAVM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.51. With this latest performance, PAVM shares gained by 15.96% in over the last four-week period, additionally plugging by 18.18% over the last 6 months – not to mention a rise of 68.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PAVM stock in for the last two-week period is set at 66.40, with the RSI for the last a single of trading hit 72.85, and the three-weeks RSI is set at 62.86 for PAVmed Inc. [PAVM]. The present Moving Average for the last 50 days of trading for this stock 2.05, while it was recorded at 2.23 for the last single week of trading, and 2.04 for the last 200 days.
PAVmed Inc. [PAVM]: An insightful look at the core fundamentals
Additionally, PAVM Total Debt to Total Capital is recorded at 188.61, with Total Debt to Total Assets ending up at 112.41.
Reflecting on the efficiency of the workforce at the company, PAVmed Inc. [PAVM] managed to generate an average of -$1,097,149 per employee.PAVmed Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.40 and a Current Ratio set at 0.40.
Earnings per share (EPS) analysis for PAVmed Inc. [PAVM] stock
With the latest financial reports released by the company, PAVmed Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -72.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PAVM.
PAVmed Inc. [PAVM]: Insider Ownership positions
There are presently around $18 million, or 9.90% of PAVM stock, in the hands of institutional investors. The top three institutional holders of PAVM stocks are: BLACKROCK INC. with ownership of 1,848,227, which is approximately 4.499% of the company’s market cap and around 2.70% of the total institutional ownership; VANGUARD GROUP INC, holding 1,642,273 shares of the stock with an approximate value of $4.06 million in PAVM stocks shares; and NORTHERN TRUST CORP, currently with $1.03 million in PAVM stock with ownership of nearly 225.462% of the company’s market capitalization.
Positions in PAVmed Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 30 institutional holders increased their position in PAVmed Inc. [NASDAQ:PAVM] by around 1,143,181 shares. Additionally, 22 investors decreased positions by around 606,952 shares, while 16 investors held positions by with 5,499,268 shares. The mentioned changes placed institutional holdings at 7,249,401 shares, according to the latest SEC report filing. PAVM stock had 14 new institutional investments in for a total of 414,770 shares, while 7 institutional investors sold positions of 355,230 shares during the same period.